H.R.2301 - Clinical Trial Cancer Mission 2020 Act113th Congress (2013-2014)
|Sponsor:||Rep. Reed, Tom [R-NY-23] (Introduced 06/06/2013)|
|Committees:||House - Energy and Commerce|
|Latest Action:||06/07/2013 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.2301 — 113th Congress (2013-2014)All Bill Information (Except Text)
Introduced in House (06/06/2013)
Clinical Trial Cancer Mission 2020 Act - Revises clinical trial registry data bank provisions of the Public Health Service Act to: (1) include a device or drug clinical trial whether or not it results in a positive or negative outcome, and (2) subject clinical trials funded by the Department of Defense (DOD) to requirements to certify information submissions to the Director of the National Institutes of Health (NIH).
Restricts funding for a grantee and makes the grantee liable to the United States for repayment of any grant amount provided, if the grantee has not submitted clinical trial information within the 30-day correction period for noncompliance.